United Therapeutics Remodulin Deal
Handy Aradigm Inhaler Key To PAH Prostacyclin Usage?
Last week s new deal between Aradigm Corp. and existing partner United Therapeutics Corp. through its wholly owned subsidiary Lung Rx Inc. to develop Remodulin (treprostinil) using the former s AERx Essence approach could provide the needed boost to put prostacyclins at the forefront of pulmonary arterial hypertension therapy (PAH), thanks to the metered-dose inhaler.
To continue reading subscribe now to BioWorld Insight
Learn More about BioWorld Insight
Already a subscriber? Sign In or Buy now to activate your subscription
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.